Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Government to revise...

    Government to revise limit of free salicylic acid content in drugs containing ASPIRIN

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-04-18T15:13:04+05:30  |  Updated On 17 Aug 2021 11:54 AM IST

    New Delhi: Government is soon going to revise the limit of free salicylic acid content in medicines containing Aspirin, as the Drugs and Techincal Advisory Board (DTAB) has shown a green flag to amend Schedule-V of the Drugs and Cosmetics Rules, 1945 for the same.


    The matter came to light during the DTAB meeting held in New Delhi earlier this month. The board reached a conclusion wherein the limit of free salicylic acid content shall be not more than 3 per cent in all medicines containing aspirin.


    DTAB deliberated the proposal and agreed to amend Schedule-V of the D&C Rules, 1945 to revise the limit of free salicylic acid content in medicines.


    The current provision under Schedule-V of the Drugs and Cosmetics Rules, 1945 reads;




    'All patent and proprietary medicines containing aspirin shall be subjected to "Free Salicylic Acid Test" and the limit of such acid shall be 0.75 per cent. Except in case of soluble type aspirin in which case the limit of such acid shall be 3 per cent.'



    Aspirin and Aspirin containing Fixed Dose Combinations (FDCs) are widely used formulations, and several such single ingredient formulations and FDCs are covered under various Pharmacopoeia and the "Free Salicylic Acid" content limit specified in such Pharmacopoeia as in Indian Pharmacopoeia (IP) 2018, the maximum limit is 3 per cent, in British Pharmacopoeia (BP) 2018, the limit is maximum 3 per cent, in US Pharmacopoeia (USP) 41, the limit is not more than 3 per cent and not more than 8 per cent for aspirin effervescent tablets for oral solution.


    DTAB deliberated the proposal and agreed to amend Schedule-V of the Drugs and Cosmetics Rules, 1945 to revise the limit of free salicylic acid content in medicines.


    Therefore, it is proposed to revise the free salicylic acid limits under Schedule-V of the Drugs and Cosmetics Rules, 1945 as:




    'All medicines containing aspirin shall be subjected to "Free Salicylic Acid Test",
    and the limit of "Free Salicylic Acid" content shall be not more than 3.0 per cent.'



    Also Read: Adverse Reactions: Cefotaxime, Oflaxicin, Cefixime told to carry Warning by CDSCO
    amendAspirinCDSCOD&C Rules 1945Drugs and Cosmetics RulesDrugs Technical Advisory BoardDTABfree salicylic acid testHealthcarepharmapharma newspharmacopoeial standardspharmanews indiasalicylic acidSchedule-Vskin creamskin diseaseUnion Health Ministry

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok